Literature DB >> 20118399

Conflicts of interest, authorship, and disclosures in industry-related scientific publications.

Rafael Fonseca, Paul Richardson, Sergio Giralt, Sagar Lonial, S Vincent Rajkumar, A Keith Stewart, William Bensinger, George Somlo, Robert Vescio, Joseph Mikhael, Craig Reeder, Rodger Tiedemann, Guido Tricot, Robert Rifkin, John Shaughnessy, Nikhil Munshi, Noopur Raje, Irene Ghobrial, Jacob Laubach, Robert Schlossman, Steven Treon, Anuj Mahindra, David Avigan, Jacalyn Rosenblatt, Sundar Jagannath, Ruben Niesvizky, Heather Landau, Selina Chen-Kiang, David S Siegel, Todd Zimmerman, Jayesh Mehta, David Vesole, Steven Rosen, Craig Hofmeister, Martha Lacy, Angela Dispenzieri, Ivan Borrello, Suzanne R Hayman, Shaji Kumar, Frances Buadi, David Dingli, Stephen Russell, Melissa Alsina Melissa Alsina, Hugo Fernandez, Vivek Roy, Denise Pereira, Edward Stadtmauer, Ravi Vij, Andrzej Jakubowiak, Suzanne Lentzsch, Kevin Song, Suzanne Trudel, Christine Chen, Donna Reece, Douglas Stewart, Seema Singhal, Raymond Comenzo, Morie A Gertz, Philip R Greipp, Brian Durie, Bart Barlogie, Kenneth Anderson, William Dalton, Morton Coleman, Susie Novis, Robert A Kyle.   

Abstract

Mesh：

Year:  2010        PMID： 20118399      PMCID： PMC2813833          DOI： 10.4065/mcp.2009.0559

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  12 in total

1.  Regulating academic-industrial research relationships--solving problems or stifling progress?

Authors:  Thomas P Stossel
Journal:  N Engl J Med       Date:  2005-09-08       Impact factor: 91.245

2.  Divergent views on managing clinical conflicts of interest.

Authors:  Thomas P Stossel
Journal:  Mayo Clin Proc       Date:  2007-08       Impact factor: 7.616

3.  Conflicts of interest, authorship, and disclosures in industry-related scientific publications: the tort bar and editorial oversight of medical journals.

Authors:  Laurence J Hirsch
Journal:  Mayo Clin Proc       Date:  2009-09       Impact factor: 7.616

4.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

5.  Antitumor activity of thalidomide in refractory multiple myeloma.

Authors:  S Singhal; J Mehta; R Desikan; D Ayers; P Roberson; P Eddlemon; N Munshi; E Anaissie; C Wilson; M Dhodapkar; J Zeddis; B Barlogie
Journal:  N Engl J Med       Date:  1999-11-18       Impact factor: 91.245

6.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Authors:  Donna M Weber; Christine Chen; Ruben Niesvizky; Michael Wang; Andrew Belch; Edward A Stadtmauer; David Siegel; Ivan Borrello; S Vincent Rajkumar; Asher Alban Chanan-Khan; Sagar Lonial; Zhinuan Yu; John Patin; Marta Olesnyckyj; Jerome B Zeldis; Robert D Knight
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

7.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Authors:  Meletios Dimopoulos; Andrew Spencer; Michael Attal; H Miles Prince; Jean-Luc Harousseau; Anna Dmoszynska; Jesus San Miguel; Andrzej Hellmann; Thierry Facon; Robin Foà; Alessandro Corso; Zvenyslava Masliak; Marta Olesnyckyj; Zhinuan Yu; John Patin; Jerome B Zeldis; Robert D Knight
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

8.  Improved survival in multiple myeloma and the impact of novel therapies.

Authors:  Shaji K Kumar; S Vincent Rajkumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; David Dingli; Stephen J Russell; John A Lust; Philip R Greipp; Robert A Kyle; Morie A Gertz
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

9.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Authors:  Jesús F San Miguel; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; Anna Dmoszynska; Kudrat M Abdulkadyrov; Rik Schots; Bin Jiang; Maria-Victoria Mateos; Kenneth C Anderson; Dixie L Esseltine; Kevin Liu; Andrew Cakana; Helgi van de Velde; Paul G Richardson
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245

10.  Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.

Authors:  Martha Q Lacy; Suzanne R Hayman; Morie A Gertz; Angela Dispenzieri; Francis Buadi; Shaji Kumar; Philip R Greipp; John A Lust; Stephen J Russell; David Dingli; Robert A Kyle; Rafael Fonseca; P Leif Bergsagel; Vivek Roy; Joseph R Mikhael; A Keith Stewart; Kristina Laumann; Jacob B Allred; Sumithra J Mandrekar; S Vincent Rajkumar
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.